These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35964531)

  • 1. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.
    Chiriacò M; Tricò D; Solini A
    Curr Opin Pharmacol; 2022 Oct; 66():102272. PubMed ID: 35964531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
    Verma S; Mudaliar S; Greasley PJ
    Adv Ther; 2024 Jan; 41(1):92-112. PubMed ID: 37943443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.
    Afsar B; Afsar RE
    Pharmacol Rep; 2023 Feb; 75(1):44-68. PubMed ID: 36534320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
    Nazari S; Mirkhani H
    Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can sodium-glucose cotransporter 2 inhibitors 'spin the thread of life'?
    Maltese G; Koufakis T; Kotsa K; Karalliedde J
    Trends Endocrinol Metab; 2023 Jan; 34(1):1-4. PubMed ID: 36357309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
    Cherney DZI; Udell JA; Drucker DJ
    Med; 2021 Nov; 2(11):1203-1230. PubMed ID: 35590197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
    Li N; Zhou H
    Curr Pharm Des; 2022; 28(26):2131-2139. PubMed ID: 35718973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.
    Gronda E; Lopaschuk GD; Arduini A; Santoro A; Benincasa G; Palazzuoli A; Gabrielli D; Napoli C
    Can J Physiol Pharmacol; 2022 Feb; 100(2):93-106. PubMed ID: 35112597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2i: beyond the glucose-lowering effect.
    Ni L; Yuan C; Chen G; Zhang C; Wu X
    Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench.
    Chen X; Hocher CF; Shen L; Krämer BK; Hocher B
    Am J Physiol Cell Physiol; 2023 Sep; 325(3):C661-C681. PubMed ID: 37519230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
    Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
    Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
    Hou YC; Zheng CM; Yen TH; Lu KC
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Bioenergetic Properties and Cardiorespiratory Fitness: A Special Effect of SGLT2i In Heart Failure?
    Farooq M; Jorde UP
    Cardiol Rev; 2023 Mar-Apr 01; 31(2):65-69. PubMed ID: 35191660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions.
    Girardi ACC; Polidoro JZ; Castro PC; Pio-Abreu A; Noronha IL; Drager LF
    Am J Physiol Cell Physiol; 2024 Sep; 327(3):C525-C544. PubMed ID: 38881421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.